β-hCG Vaccine

Alternative Name: β-human chorionic gonadotropin

Description: β-human chorionic gonadotropin (β-hCG) is a candidate immunogens to develop immunocontraceptive vaccine for human application.

Product Details

User: Female

Hormonal: No

Duration Type: Short-acting

Multipurpose Preventive Technology (MPT): No

Status Details

Developer: Talwar Research Foundation, Indian Council for Medical Research

Project Phase: Pre-Clinical and Clinical Development

Development Stage: Phase II

Active Development: Unknown

Status Details:
  • Phase II trials were completed in 1994. After a phase of inactivity, work began on a recombinant vaccine, which could be amenable to industrial production. Preclinical work on the reconfigured vaccine has been undertaken and there are plans to restart clinical trials.

Additional Information

References:
  • Talwar GP, et al. (1994) A vaccine that prevents pregnancy in women. Proc Natl Acad Sci. 30;91(18):8532-6.

  • Talwar GP, et al. (2015) Advances in development of a contraceptive vaccine against human chorionic gonadotropin. Expert Opinion on Biological Therapy. 15:8.

Footnotes:
  • See also entry on CTP of β-hCG vaccine.

Vertical Tabs

Print